At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,864 enrolled
Drug / intervention
semaglutide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating semaglutide, sitagliptin, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 1,864 participants across 242 sites in 15 countries.
Detailed Summary
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesArgentina, Brazil, France, Germany, India, Israel, Japan, Mexico, Romania, Russia, South Africa, Turkey (Türkiye), Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartFeb 2016
Primary CompletionFeb 2017
Study CompletionMar 2018
TodayJul 2026
First PostedNov 18, 2015
Enrollment StartFeb 15, 2016
Primary CompletionFeb 14, 2017
Study CompletionMar 28, 2018
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 10.6 years ago
Interventions
semaglutidedrug
Oral administration once-daily
sitagliptindrug
Oral administration once-daily
placebodrug
Oral administration once-daily